Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 14/20 | 1.00 |
| ▸ | WDR77 | Q9BQA1 | 14/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15839368 | 0.87 | PRMT5 (0.78) | PRMT5WDR77ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL15824983 | 0.83 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15824961 | 0.79 | PRMT5 (0.72) | PRMT5WDR77 | |
| SCHEMBL4886787 | 0.79 | PRMT5 (0.65) | PRMT5WDR77ALDH1A1GAALMNA | |
| SCHEMBL30019323 | 0.78 | CARM1 (0.74) | PRMT5WDR77LMNA | |
| SCHEMBL23175225 | 0.77 | PRMT5 (0.69) | PRMT5WDR77 | |
| SCHEMBL21033282 | 0.77 | PRMT5 (0.67) | PRMT5WDR77 | |
| SCHEMBL4102007 | 0.75 | PRMT5 (0.59) | PRMT5WDR77HPGD | |
| SCHEMBL4104809 | 0.75 | PRMT5 (0.59) | PRMT5WDR77HPGD | |
| SCHEMBL15836135 | 0.74 | PRMT5 (1.00) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150758-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170240537-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240537-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240537-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-08-24 | — | — | US | disclosed |
| US-9611257-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611257-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611257-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20170088541-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088541-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088541-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9365555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. | 2016-06-14 | — | — | US | disclosed |
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344463-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344463-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344463-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20140213582-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213582-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213582-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2014100764-A2 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | PRMT5, PRMT1, PRMT7 | PRMT5 1/4885WDR77 18/4885ALDH1A1 2679/4885 |
| US-20170088541-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885ALDH1A1 2460/4885 |
| US-20140213582-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885ALDH1A1 2460/4885 |
| US-20150344463-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 54/4885ALDH1A1 2426/4885 |
| US-10150758-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885ALDH1A1 2460/4885 |
| US-20170240537-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 54/4885ALDH1A1 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.